FierceBiotech

PATH Malaria Vaccine Initiative and Crucell to test new malaria vaccine approach

LEIDEN, The Netherlands, July 29, 2009 - The US-based PATH Malaria Vaccine Initiative (MVI), the United States Agency for International Development (USAID) Malaria Vaccine Development Program (MVDP), ...
FierceBiotech

Crucell and Harvard (BIDMC) Join Forces with IAVI to Advance AdVac®-based AIDS Vaccine

Leiden, the Netherlands (August 11, 2010) - Dutch biopharmaceutical company Crucell N.V. (NYSE Euronext, NASDAQ: CRXL; Swiss Exchange: CRX) today announces its intention to participate in an ...
Pressemitteilungen

Crucell and US Navy Sign Agreement to Test AdVac®-based Vaccine Against Anthrax and Plague

Leiden, The Netherlands, August 17, 2005 - Dutch biotechnology company Crucell N.V. (Euronext, NASDAQ: CRXL) announced today that it has signed a Cooperative Research and Development Agreement (CRADA) ...
GEN

Aeras Commits $5M to Crucell for Continued TB Research

AdVac-based vaccine is now in a Phase I trial. Crucell will receive up to $5 million from Aeras Global TB Vaccine Foundation to support the advanced development of the candidate AdVac-based ...
FiercePharma

Bavarian Nordic Announces Initiation of Phase 1 Clinical Trial for the Ebola Vaccine Regimen of MVA-BN® Filo and Janssen's AdVac® technology

First human trial of the MVA-BN® Filo/AdVac® preventative Ebola vaccine regimen initiated in the UK Additional trials soon to be initiated in United States and Africa Company now expects 2 million ...